Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy.

Authors

• Ruben Rhoades
• Ron Leong
• Jason Kopenitz
• Brandi Thoma
• Lydia McDermott
• Joseph Dovidio
• Shannon Barletti
• Jerald Z Gong
• Howard T Massey
• Steven E McKenzie
• J Eduardo Rame
• Nawar Al-Rawas

Publication/Presentation Date

7-1-2021

Volume

203

First Page

1

Last Page

4

ISSN

1879-2472

Published In/Presented At

Rhoades, R., Leong, R., Kopenitz, J., Thoma, B., McDermott, L., Dovidio, J., Barletti, S., Gong, J. Z., Massey, H. T., McKenzie, S. E., Rame, J. E., & Al-Rawas, N. (2021). Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy. Thrombosis research, 203, 1–4. https://doi.org/10.1016/j.thromres.2021.04.008

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

33894473

Department(s)

Administration and Leadership

Document Type

Article